4//SEC Filing
Deck Kelly 4
Accession 0000950142-24-001489
CIK 0002007919other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:09 PM ET
Size
5.9 KB
Accession
0000950142-24-001489
Insider Transaction Report
Form 4
Deck Kelly
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2024-05-30+175,000→ 175,000 totalExercise: $15.86Exp: 2034-05-30→ Common Stock (175,000 underlying)
Footnotes (2)
- [F1]This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
- [F2]Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Documents
Issuer
Inhibrx Biosciences, Inc.
CIK 0002007919
Entity typeother
Related Parties
1- filerCIK 0001819427
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 6:09 PM ET
- Size
- 5.9 KB